card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search
hero bg-3270_young woman scientist in laboratory working

Affinity Maturation

specifica-knockout-logo

 

Antibodies generated using in vitro or in vivo techniques may have desired biological activity but be deficient in other properties. Specifica has adapted the Generation 3 library platform to affinity mature antibodies from any source, guaranteeing at least 10-fold affinity increases — while simultaneously improving developability.

 

The process involves the initial creation of phase 1 libraries based on the antibody to be matured in which HCDR1/2, LCDR1/2, LCDR3, and HCDR3 if needed, are replaced with scaffold-matching CDRs from the Generation 3 platform. This is followed by yeast display, with the best outputs after sorting for improved affinity combined in a phase 2 library.

 

As sequence liabilities are purged from the CDRs used, developability improvement occurs simultaneously with affinity maturation, which ranges from 10- to 200-fold over the starting antibody affinity.

 

Low affinity is the most frequently required improvement, but Specifica can also provide optimization of developability, cross-reactivity and pH modulation.

Related Services

card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate

Discovery Sciences

Learn more
card-3259_man in laboratory with tablet for medical analysis

Protein Sciences

Learn more
card-3234_Liquid drop from pipette to test tube

Antibody Libraries

Learn more
card-3229_test tubes for testing

In Vitro Immunology

Learn more
card-3276_A medical scientist is preparing a pathological specimen for diagnosis

Discovery Science Specialty Testing Services

Learn more
card-3259_man in laboratory with tablet for medical analysis

Additional Specialty Testing Services

Learn more